share_log

EyePoint Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

EyePoint Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

EyePoint Pharmaceuticals | 144：拟议出售证券
美股SEC公告 ·  05/14 16:46

Moomoo AI 已提取核心信息

EyePoint Pharmaceuticals, Inc. Director David R. Guyer is set to sell 71,850 shares of common stock on 05/14/2024, as announced in a recent filing. The shares, valued at an aggregate market value of $897,407, were acquired through a series of Restricted Stock Unit (RSU) vestings and a stock option exercise. The RSUs vested on three separate occasions: 1,900 shares on 02/28/2021, 2,500 shares on 06/22/2022, and 3,000 shares on 02/09/2023, all as part of compensation from the issuer. Additionally, 64,450 shares were obtained through a stock option exercise on 05/14/2024, paid for with cash. The planned sale follows a period where no securities transactions were reported in the past three months. The notice of the intended sale was filed on the same date as the sale, with the plan for the transaction having been adopted earlier on 01/25/2024.
EyePoint Pharmaceuticals, Inc. Director David R. Guyer is set to sell 71,850 shares of common stock on 05/14/2024, as announced in a recent filing. The shares, valued at an aggregate market value of $897,407, were acquired through a series of Restricted Stock Unit (RSU) vestings and a stock option exercise. The RSUs vested on three separate occasions: 1,900 shares on 02/28/2021, 2,500 shares on 06/22/2022, and 3,000 shares on 02/09/2023, all as part of compensation from the issuer. Additionally, 64,450 shares were obtained through a stock option exercise on 05/14/2024, paid for with cash. The planned sale follows a period where no securities transactions were reported in the past three months. The notice of the intended sale was filed on the same date as the sale, with the plan for the transaction having been adopted earlier on 01/25/2024.
正如在最近的一份文件中宣布的那样，EyePoint Pharmicals, Inc.董事戴维·盖尔定于2024年5月14日出售71,850股普通股。这些股票的总市值为897,407美元，是通过一系列限制性股票单位（RSU）归属和股票期权行使收购的。限制性股票单位在三个不同的场合归属：2021年2月28日归属于1,900股，2022年6月22日归属于2,500股，2023年9月2日归属于3,000股，全部作为发行人薪酬的一部分。此外，2024年5月14日通过股票期权行使获得了64,450股股票，以现金支付。计划中的出售是在过去三个月中没有报告任何证券交易之后进行的。拟出售通知与出售的同一天提交，交易计划已于2024年1月25日早些时候通过。
正如在最近的一份文件中宣布的那样，EyePoint Pharmicals, Inc.董事戴维·盖尔定于2024年5月14日出售71,850股普通股。这些股票的总市值为897,407美元，是通过一系列限制性股票单位（RSU）归属和股票期权行使收购的。限制性股票单位在三个不同的场合归属：2021年2月28日归属于1,900股，2022年6月22日归属于2,500股，2023年9月2日归属于3,000股，全部作为发行人薪酬的一部分。此外，2024年5月14日通过股票期权行使获得了64,450股股票，以现金支付。计划中的出售是在过去三个月中没有报告任何证券交易之后进行的。拟出售通知与出售的同一天提交，交易计划已于2024年1月25日早些时候通过。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间